|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashiguchi Y, Muro K, Saito Y, Ito Y,
Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M,
et al Japanese Society for Cancer of the Colon Rectum, : Japanese
Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019
for the treatment of colorectal cancer. Int J Clin Oncol. 25:1–42.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Folprecht G, Gruenberger T, Bechstein WO,
Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher
J, Weitz J, et al: Tumour response and secondary resectability of
colorectal liver metastases following neoadjuvant chemotherapy with
cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol.
11:38–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Majeed AW: Surgery for colorectal liver
metastases with hepatic lymph node involvement: A systematic
review. Br J Surg. 87:17372000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martin LW and Warren RS: Current
management of colorectal liver metastases. Surg Oncol Clin N Am.
9:853–878. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Penna C and Nordlinger B: Colorectal
metastasis (liver and lung). Surg Clin North Am. 82:1075–1090,
x-xi. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fidler IJ and Kripke ML: Metastasis
results from preexisting variant cells within a malignant tumor.
Science. 197:893–895. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Futakuchi M, Nannuru KC, Varney ML,
Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY and Singh RK:
Transforming growth factor-beta signaling at the tumor-bone
interface promotes mammary tumor growth and osteoclast activation.
Cancer Sci. 100:71–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagashima T, Yamaguchi K, Urakami K,
Shimoda Y, Ohnami S, Ohshima K, Tanabe T, Naruoka A, Kamada F,
Serizawa M, et al: Japanese version of The Cancer Genome Atlas,
JCGA, established using fresh frozen tumors obtained from 5143
cancer patients. Cancer Sci. 111:687–699. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Japanese ethical guidelines for human
genome/gene analysis research. https://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/genome/0504sisin.htmlMarch
25–2021
|
|
12
|
Ion Reporter Software User Guide, .
Tumor-Normal pair workflow. https://tools.thermofisher.com/content/sfs/manuals/IonReporter_v50_Help.pdfMarch
25–2021
|
|
13
|
Torrent Suite v4.4.3 User and Admin Guide,
. https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0019144_TorrentSuite_5_14_UG.pdfMarch
25–2021
|
|
14
|
Robinson JT, Thorvaldsdóttir H, Winckler
W, Guttman M, Lander ES, Getz G and Mesirov JP: Integrative
genomics viewer. Nat Biotechnol. 29:24–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bamford S, Dawson E, Forbes S, Clements J,
Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR,
et al: The COSMIC (Catalogue of Somatic Mutations in Cancer)
database and website. Br J Cancer. 91:355–358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landrum MJ, Lee JM, Riley GR, Jang W,
Rubinstein WS, Church DM and Maglott DR: ClinVar: Public archive of
relationships among sequence variation and human phenotype. Nucleic
Acids Res. 42:D980–D985. 2014. View Article : Google Scholar
|
|
17
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of
genetic variation. Nucleic Acids Res. 308–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
UniProt Consortium: UniProt: A hub for
protein information. Nucleic Acids Res. 43:D204–D212. 2015.
View Article : Google Scholar
|
|
19
|
Wishart DS, Knox C, Guo AC, Shrivastava S,
Hassanali M, Stothard P, Chang Z and Woolsey J: DrugBank: A
comprehensive resource for in silico drug discovery and
exploration. Nucleic Acids Res. 34:D668–D672. 2006. View Article : Google Scholar
|
|
20
|
Nagashima T, Shimoda Y, Tanabe T, Naruoka
A, Saito J, Serizawa M, Ohshima K, Urakami K, Ohnami S, Ohnami S,
et al: Optimizing an ion semiconductor sequencing data analysis
method to identify somatic mutations in the genomes of cancer cells
in clinical tissue samples. Biomed Res. 37:359–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimoda Y, Nagashima T, Urakami K, Tanabe
T, Saito J, Naruoka A, Serizawa M, Mochizuki T, Ohshima K, Ohnami
S, et al: Integrated next-generation sequencing analysis of whole
exome and 409 cancer-related genes. Biomed Res. 37:367–379. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Urakami K, Shimoda Y, Ohshima K, Nagashima
T, Serizawa M, Tanabe T, Saito J, Usui T, Watanabe Y, Naruoka A, et
al: Next generation sequencing approach for detecting 491 fusion
genes from human cancer. Biomed Res. 37:51–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sadanandam A, Lyssiotis CA, Homicsko K,
Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA,
Grotzinger C, Del Rio M, et al: A colorectal cancer classification
system that associates cellular phenotype and responses to therapy.
Nat Med. 19:619–625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Polanska UM and Orimo A:
Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting
mesenchymal cells. J Cell Physiol. 228:1651–1657. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishii G, Ochiai A and Neri S: Phenotypic
and functional heterogeneity of cancer-associated fibroblast within
the tumor microenvironment. Adv Drug Deliv Rev. 99:186–196. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kyutoku M, Taniyama Y, Katsuragi N,
Shimizu H, Kunugiza Y, Iekushi K, Koibuchi N, Sanada F, Oshita Y
and Morishita R: Role of periostin in cancer progression and
metastasis: Inhibition of breast cancer progression and metastasis
by anti-periostin antibody in a murine model. Int J Mol Med.
28:181–186. 2011.PubMed/NCBI
|
|
30
|
Erkan M, Kleeff J, Gorbachevski A, Reiser
C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA and Friess
H: Periostin creates a tumor-supportive microenvironment in the
pancreas by sustaining fibrogenic stellate cell activity.
Gastroenterology. 132:1447–1464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kudo Y, Ogawa I, Kitajima S, Kitagawa M,
Kawai H, Gaffney PM, Miyauchi M and Takata T: Periostin promotes
invasion and anchorage-independent growth in the metastatic process
of head and neck cancer. Cancer Res. 66:6928–6935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Puglisi F, Puppin C, Pegolo E, Andreetta
C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante
G, et al: Expression of periostin in human breast cancer. J Clin
Pathol. 61:494–498. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moniuszko T, Wincewicz A, Koda M,
Domysławska I and Sulkowski S: Role of periostin in esophageal,
gastric and colon cancer. Oncol Lett. 12:783–787. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sodek J, Ganss B and McKee MD:
Osteopontin. Crit Rev Oral Biol Med. 11:279–303. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang J, Takahashi K, Takahashi F, Shimizu
K, Ohshita F, Kameda Y, Maeda K, Nishio K and Fukuchi Y:
Differential osteopontin expression in lung cancer. Cancer Lett.
171:215–222. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song G, Cai QF, Mao YB, Ming YL, Bao SD
and Ouyang GL: Osteopontin promotes ovarian cancer progression and
cell survival and increases HIF-1alpha expression through the
PI3-K/Akt pathway. Cancer Sci. 99:1901–1907. 2008.PubMed/NCBI
|
|
37
|
Kim JY, Bae BN, Kim KS, Shin E and Park K:
Osteopontin, CD44, and NFkappaB expression in gastric
adenocarcinoma. Cancer Res Treat. 41:29–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Likui W, Hong W and Shuwen Z: Clinical
significance of the upregulated osteopontin mRNA expression in
human colorectal cancer. J Gastrointest Surg. 14:74–81. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bramwell VH, Tuck AB, Chapman JA, Anborgh
PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF,
Pritchard KI, et al: Assessment of osteopontin in early breast
cancer: Correlative study in a randomised clinical trial. Breast
Cancer Res. 16:R82014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao M, Liang F, Zhang B, Yan W and Zhang
J: The impact of osteopontin on prognosis and clinicopathology of
colorectal cancer patients: A systematic meta-analysis. Sci Rep.
5:127132015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tokunaga T, Nakamura M, Oshika Y, Abe Y,
Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T,
et al: Thrombospondin 2 expression is correlated with inhibition of
angiogenesis and metastasis of colon cancer. Br J Cancer.
79:354–359. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
de Fraipont F, Nicholson AC, Feige JJ and
Van Meir EG: Thrombospondins and tumor angiogenesis. Trends Mol
Med. 7:401–407. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim H, Watkinson J, Varadan V and
Anastassiou D: Multi-cancer computational analysis reveals
invasion-associated variant of desmoplastic reaction involving
INHBA, THBS2 and COL11A1. BMC Med Genomics. 3:512010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tian Q, Liu Y, Zhang Y, Song Z, Yang J,
Zhang J, Guo T, Gao W, Dai F and He C: THBS2 is a biomarker for
AJCC stages and a strong prognostic indicator in colorectal cancer.
J BUON. 23:1331–1336. 2018.PubMed/NCBI
|
|
45
|
Rich JN, Shi Q, Hjelmeland M, Cummings TJ,
Kuan CT, Bigner DD, Counter CM and Wang XF: Bone-related genes
expressed in advanced malignancies induce invasion and metastasis
in a genetically defined human cancer model. J Biol Chem.
278:15951–15957. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kuan CT, Wakiya K, Dowell JM, Herndon JE
II, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ and Bigner DD:
Glycoprotein nonmetastatic melanoma protein B, a potential
molecular therapeutic target in patients with glioblastoma
multiforme. Clin Cancer Res. 12:1970–1982. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rose AA, Pepin F, Russo C, Abou Khalil JE,
Hallett M and Siegel PM: Osteoactivin promotes breast cancer
metastasis to bone. Mol Cancer Res. 5:1001–1014. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rose AA, Annis MG, Dong Z, Pepin F,
Hallett M, Park M and Siegel PM: ADAM10 releases a soluble form of
the GPNMB/Osteoactivin extracellular domain with angiogenic
properties. PLoS One. 5:e120932010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rose AA, Grosset AA, Dong Z, Russo C,
Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park
M, et al: Glycoprotein nonmetastatic B is an independent prognostic
indicator of recurrence and a novel therapeutic target in breast
cancer. Clin Cancer Res. 16:2147–2156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Taya M and Hammes SR: Glycoprotein
non-metastatic melanoma protein B (GPNMB) and cancer: A novel
potential therapeutic target. Steroids. 133:102–107. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou LT, Liu FY, Li Y, Peng YM, Liu YH and
Li J: Gpnmb/osteoactivin, an attractive target in cancer
immunotherapy. Neoplasma. 59:1–5. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Selim AA: Osteoactivin bioinformatic
analysis: Prediction of novel functions, structural features, and
modes of action. Med Sci Monit. 15:MT19–MT33. 2009.
|
|
53
|
Singh M, Del Carpio-Cano F, Belcher JY,
Crawford K, Frara N, Owen TA, Popoff SN and Safadi FF: Functional
roles of osteoactivin in normal and disease processes. Crit Rev
Eukaryot Gene Expr. 20:341–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mertsch S, Schurgers LJ, Weber K, Paulus W
and Senner V: Matrix gla protein (MGP): An overexpressed and
migration-promoting mesenchymal component in glioblastoma. BMC
Cancer. 9:3022009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kuzontkoski PM, Mulligan-Kehoe MJ, Harris
BT and Israel MA: Inhibitor of DNA binding-4 promotes angiogenesis
and growth of glioblastoma multiforme by elevating matrix GLA
levels. Oncogene. 29:3793–3802. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gheorghe SR and Crăciun AM: Matrix Gla
protein in tumoral pathology. Clujul Med. 89:319–321.
2016.PubMed/NCBI
|
|
57
|
Caiado H, Conceição N, Tiago D, Marreiros
A, Vicente S, Enriquez JL, Vaz AM, Antunes A, Guerreiro H, Caldeira
P, et al: Evaluation of MGP gene expression in colorectal cancer.
Gene. 723:1441202020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hope NR and Murray GI: The expression
profile of RNA-binding proteins in primary and metastatic
colorectal cancer: Relationship of heterogeneous nuclear
ribonucleoproteins with prognosis. Hum Pathol. 42:393–402. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vakiani E, Janakiraman M, Shen R, Sinha R,
Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al:
Comparative genomic analysis of primary versus metastatic
colorectal carcinomas. J Clin Oncol. 30:2956–2962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schrijver WAME, Selenica P, Lee JY, Ng
CKY, Burke KA, Piscuoglio S, Berman SH, Reis-Filho JS, Weigelt B,
van Diest PJ, et al: Mutation profiling of key cancer genes in
primary breast cancers and their distant metastases. Cancer Res.
78:3112–3121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ding L, Ley TJ, Larson DE, Miller CA,
Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan
MD, et al: Clonal evolution in relapsed acute myeloid leukaemia
revealed by whole-genome sequencing. Nature. 481:506–510. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Johnson BE, Mazor T, Hong C, Barnes M,
Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et
al: Mutational analysis reveals the origin and therapy-driven
evolution of recurrent glioma. Science. 343:189–193. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Harada K, Okamoto W, Mimaki S, Kawamoto Y,
Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, et al:
Comparative sequence analysis of patient-matched primary colorectal
cancer, metastatic, and recurrent metastatic tumors after adjuvant
FOLFOX chemotherapy. BMC Cancer. 19:2552019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gagnière J, Dupré A, Gholami SS, Pezet D,
Boerner T, Gönen M, Kingham TP, Allen PJ, Balachandran VP, De
Matteo RP, et al: Is hepatectomy justified for BRAF mutant
colorectal liver metastases?: A multi-institutional analysis of
1497 patients. Ann Surg. 271:147–154. 2020. View Article : Google Scholar
|
|
65
|
Wu Y, Denhardt DT and Rittling SR:
Osteopontin is required for full expression of the transformed
phenotype by the ras oncogene. Br J Cancer. 83:156–163. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Nemoto H, Rittling SR, Yoshitake H, Furuya
K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT and Noda M:
Osteopontin deficiency reduces experimental tumor cell metastasis
to bone and soft tissues. J Bone Miner Res. 16:652–659. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wu XL, Lin KJ, Bai AP, Wang WX, Meng XK,
Su XL, Hou MX, Dong PD, Zhang JJ, Wang ZY, et al: Osteopontin
knockdown suppresses the growth and angiogenesis of colon cancer
cells. World J Gastroenterol. 20:10440–10448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wei R, Wong JPC and Kwok HF: Osteopontin -
a promising biomarker for cancer therapy. J Cancer. 8:2173–2183.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rose AAN, Biondini M, Curiel R and Siegel
PM: Targeting GPNMB with glembatumumab vedotin: Current
developments and future opportunities for the treatment of cancer.
Pharmacol Ther. 179:127–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
